Search

Your search keyword '"EROL, Cihan"' showing total 135 results
Start Over Author "EROL, Cihan"
135 results on '"EROL, Cihan"'

1. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

Author

Sekmek, Serhat, Ozsan Çelebi, Sema Nur, Bayram, Dogan, Erol, Cihan, Kos, Fahriye Tugba, Sendur, Mehmet Ali Nahit, Altıntas, Yunus Emre, Tuylu, Tugba, Yildirim, Sedat, Biter, Sedat, Kıdı, Mehmet Mutlu, Bayram, Ertugrul, Majidova, Nargiz, Bayoglu, Ibrahim Vedat, Atak, Mehmetcan, Baskurt, Kadriye, Akbas, Sinem, Alkan, Ali, Bayramgil, Ayberk, Aslan, Ferit, Sahin, Elif, Balcik, Onur Yazdan, Bayhan, Ahmet Ziya, Saray, Seray, Arpaci, Erkan, and Ergun, Yakup

Published
2024
Full Text
View/download PDF

2. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Author

Kahraman, Seda, Karakaya, Serdar, Kaplan, Muhammed Ali, Goksu, Sema Sezgin, Ozturk, Akin, Isleyen, Zehra Sucuoglu, Hamdard, Jamshid, Yildirim, Sedat, Dogan, Tolga, Isik, Selver, Celebi, Abdussamet, Gulbagci, Burcu Belen, Paksoy, Nail, Dogan, Mutlu, Turk, Haci Mehmet, Bilici, Ahmet, Tatli, Ali Murat, Akbas, Sinem, Turan, Nedim, Hacibekiroglu, Ilhan, Dogu, Gamze Gokoz, Aydiner, Adnan, Sumbul, Ahmet Taner, Akyurek, Serap, Yalciner, Merih, Demirkazik, Ahmet, Gursoy, Pinar, Aykan, Musa Baris, Sahin, Elif, Karadag, İbrahim, Kostek, Osman, Er, Muhammed Muhiddin, Artaç, Mehmet, Duzkopru, Yakup, Aydin, Dincer, Isik, Deniz, Karakas, Yusuf, Kilickap, Saadettin, Erol, Cihan, Demir, Bilgin, Civelek, Burak, Ergun, Yakup, Akinci, Muhammed Bulent, Dogan, Izzet, Karadurmus, Nuri, Yumuk, Perran Fulden, and Sendur, Mehmet Ali Nahit

Published
2024
Full Text
View/download PDF

3. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

Author

Bilici, Ahmet, Koca, Sinan, Karaagac, Mustafa, Aydin, Sabin Goktas, Eraslan, Emrah, Kaplan, Muhammed Ali, Ocak, Birol, Goksu, Sema Sezgin, Paydas, Semra, Akgul, Fahri, Derin, Sumeyye, Ergun, Yakup, Yekeduz, Emre, Erol, Cihan, Ozyukseler, Deniz Tataroglu, Demiray, Atike Gokcen, Karaca, Mustafa, Guc, Zeynep Gulsum, Menekse, Serkan, Cinkir, Havva Yesil, Gumusay, Ozge, Sakin, Abdullah, Ozkul, Ozlem, Demir, Hacer, Erdem, Dilek, Besiroglu, Mehmet, Unal, Olcun Umit, Acar, Ramazan, Koral, Lokman, Sahin, Suleyman, Sakalar, Teoman, Bahceci, Aykut, Ozveren, Ahmet, Gunaydin, Ulug Mutlu, Seker, Mehmet Metin, Sunar, Veli, Dal, Pinar, Artac, Mehmet, and Turhal, Serdar

Published
2023
Full Text
View/download PDF

4. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Author

Yekedüz, Emre, Özbay, Mehmet Fatih, Çağlayan, Dilek, Yıldırım, Atila, Erol, Cihan, Yıldırım, Hasan Çağrı, Tunç, Sezai, Özyurt, Neslihan, Özdemir, Feyyaz, Şendur, Mehmet Ali Nahit, Işıkdoğan, Abdurrahman, Kılıçkap, Saadettin, Ürün, Yüksel, Yalçın, Şuayib, Artaç, Mehmet, Coşkun, Hasan Şenol, and Utkan, Güngör

Published
2022
Full Text
View/download PDF

5. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Author

Yekedüz, Emre, Tural, Deniz, Ertürk, İsmail, Karakaya, Serdar, Erol, Cihan, Ercelep, Özlem, Arslan, Çağatay, Sever, Özlem Nuray, Kılıçkap, Saadettin, Şentürk Öztaş, Nihan, Küçükarda, Ahmet, Can, Orçun, Öksüzoğlu, Berna, Şendur, Mehmet Ali, Karadurmuş, Nuri, and Ürün, Yüksel

Published
2022
Full Text
View/download PDF

7. Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Author

Gürbüz, Mustafa, Akkuş, Erman, Sakin, Abdullah, Urvay, Semiha, Demiray, Atike Gökçen, Şahin, Süleyman, Şakalar, Teoman, Erol, Cihan, Şendur, Mehmet Ali Nahit, Şahin, Ahmet Bilgehan, Çubukçu, Erdem, Güven, Deniz Can, Kılıçkap, Saadettin, Ergün, Yakup, Uncu, Doğan, Turhal, Nazım Serdar, Üskent, Necdet, Çınkır, Havva Yeşil, Demir, Atakan, Acar, Ramazan, Karadurmuş, Nuri, Türker, Sema, Altınbaş, Mustafa, Karaoğlan, Mert, and Şenler, Filiz Çay

Published
2022
Full Text
View/download PDF

8. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Author

Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Açıkgöz, Özgür, Sezer, Ahmet, Gürbüz, Mustafa, Ak, Naziye, Yücel, Şebnem, Ayhan, Murat, Erol, Cihan, Demirkıran, Aykut, Mandel, Nil Molinas, Shbair, Abdallah, Gökmen, İvo, Başoğlu, Tuğba, Paydaş, Semra, Demiray, Atike Gökçen, İriağaç, Yakup, Şakalar, Teoman, Zeynelgil, Esra, Tatlı, Ali Murat, Bahçeci, Aykut, Güven, Deniz Can, Caner, Burcu, Can, Alper, Gülmez, Ahmet, Karakaş, Yusuf, Yalçın, Bülent, Demirkazık, Ahmet, Bilici, Ahmet, Aydıner, Adnan, Yumuk, Perran Fulden, and Şendur, Mehmet Ali Nahit

Published
2022
Full Text
View/download PDF

9. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Author

Yücel, Kadriye Bir, Yekedüz, Emre, Karakaya, Serdar, Tural, Deniz, Ertürk, İsmail, Erol, Cihan, Ercelep, Özlem, Öztaş, Nihan Şentürk, Arslan, Çağatay, Uçar, Gökhan, Küçükarda, Ahmet, Sever, Özlem Nuray, Kılıçkap, Saadettin, Can, Orçun, Yazgan, Satı Coşkun, Öksüzoğlu, Berna, Karadurmuş, Nuri, Şendur, Mehmet Ali, and Ürün, Yüksel

Published
2022
Full Text
View/download PDF

12. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Author

Bilgin, Burak, Sendur, Mehmet Ali Nahit, Yucel, Sebnem, Celik, Emir, Ozyukseler, Deniz Tataroglu, Ayhan, Murat, Basoglu, Tugba, Ilhan, Aysegul, Akdeniz, Nadiye, Gulmez, Ahmet, Dogan, Izzet, Aktas, Burak Yasin, Gurbuz, Mustafa, Koca, Sinan, Paydas, Semra, Tatli, Ali Murat, Cinkir, Havva Yesil, Alan, Ozkan, Erol, Cihan, Hizal, Mutlu, Kut, Engin, Menevse, Serkan, Sakalar, Teoman, Taskaynatan, Halil, Deniz, Gulhan Ipek, Karaagac, Mustafa, Avci, Okan, Sen, Erdem, Karatas, Fatih, Akinci, Muhammed Bulent, Dede, Didem Sener, Demir, Atakan, Demirkazık, Ahmet, Oksuzoglu, Berna, Kilickap, Sadettin, Yumuk, Fulden, and Yalcin, Bulent

Published
2021
Full Text
View/download PDF

13. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study

Author

Akdeniz, Nadiye, Kaplan, Muhammet Ali, Uncu, Doğan, İnanç, Mevlüde, Kaya, Serap, Dane, Faysal, Küçüköner, Mehmet, Demirci, Ayşe, Bilici, Mehmet, Durnalı, Ayşe Gök, Koral, Lokman, Şendur, Mehmet Ali Nahit, Erol, Cihan, Türkmen, Esma, Ölmez, Ömer Fatih, Açıkgöz, Özgür, Laçin, Şahin, Şahinli, Hayriye, Urakçı, Zuhat, and Işıkdoğan, Abdurrahman

Published
2021
Full Text
View/download PDF

14. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes.

Author

Ozbay, Mehmet Fatih, Harputluoglu, Hakan, Karaca, Mustafa, Tekin, Omer, Şendur, Mehmet Ali Nahit, Kaplan, Muhammed Ali, Sahin, Berksoy, Geredeli, Caglayan, Teker, Fatih, Tural, Deniz, Saglam, Sezer, Çil, Timuçin, Bilici, Ahmet, Erol, Cihan, Kalkan, Ziya, Bayram, Ertugrul, Selvi, Oguzhan, Gültürk, İlkay, Göksu, Sema Sezgin, and Tatlı, Ali Murat

Subjects
DRUG toxicity, CANCER relapse, SURVIVAL rate, PROTEIN-tyrosine kinase inhibitors, HYPERTENSION, SORAFENIB, DESCRIPTIVE statistics, RETROSPECTIVE studies, KAPLAN-Meier estimator, PROGRESSION-free survival, CANCER fatigue, COMPARATIVE studies, HEPATOCELLULAR carcinoma, LIVER transplantation, OVERALL survival
Abstract

Simple Summary: Liver cancer can sometimes come back after a liver transplant, which creates serious health challenges for patients. In this study, two medicines, sorafenib and regorafenib, were used to treat patients with this type of recurring cancer. Patients started with sorafenib, and if this medicine stopped working or caused too many side effects, they switched to regorafenib. The results showed that using these medicines one after the other could help patients live longer. However, these treatments can also lead to strong side effects, so patients need careful monitoring. This study highlights the importance of personalized care for people facing a return of liver cancer after a transplant. Background and Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed HCC in this unique setting. This study aimed to assess the efficacy of Sorafenib and Regorafenib in patients with HCC who experienced recurrence after liver transplantation. We focused on survival outcomes, treatment responses, and the management of side effects in this patient group. Methods: We conducted a retrospective analysis of 73 patients who experienced HCC recurrence post-liver transplantation between 2012 and 2022 across 11 oncology centers in Turkey. Patients were categorized according to Child–Pugh classification and treated with sorafenib as first-line therapy and Regorafenib in case of progression. Survival rates were analyzed using the Kaplan–Meier method, and risk factors were evaluated using Cox regression analysis. Results: Of the 73 patients included in the study, 62 were male (84.9%), and 11 were female (15.1%), with a mean age of 61.5 ± 10.9 years. All patients received sorafenib as first-line treatment. Among patients who experienced progression with sorafenib or discontinued treatment due to toxicity, 45.2% (n = 33) continued treatment with regorafenib. The median progression-free survival (PFS1) time with sorafenib was 5.6 months, and the one-year survival rate was 24.3%. The median progression-free survival (PFS2) time with regorafenib, which was administered as second-line treatment, was also calculated as 5.9 months. Overall survival (OS) duration was determined as 35.9 months. The most common side effects associated with both drugs included fatigue, hand and foot syndrome, and hypertension. Significantly better survival outcomes were shown in the Child–Pugh A group compared to other patients. Conclusions: These results suggest that Sorafenib and Regorafenib treatments offer a survival advantage in patients with relapsed HCC post-transplantation. However, individualized treatment strategies and close follow-up are crucial for optimizing outcomes. Further studies are needed to refine therapeutic protocols and enhance the care of this specific patient group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Author

Erol, Cihan, Sendur, Mehmet Nahit, Bilgetekin, Irem, Garbioglu, Duygu, Hamdard, Jamshid, Akbas, Sinem, Hizal, Mutlu, Arslan, Cagatay, Sevinc, Alper, Kucukarda, Ahmet, Erdem, Dilek, Kahraman, Seda, Cakir, Emre, Demirkiran, Aykut, On, Sercan, Dogan, Izzet, Erdogan, Atike, Koca, Sinan, Kubilay, Pinar, Eren, Orhan, Cilbir, Ebru, Celik, Emir, Araz, Murat, Ozyukseler, Deniz, Yildirim, Mahmut, Bahceci, Aykut, Taskaynatan, Halil, Oyman, Abdilkerim, Deniz, Gulhan, Menekse, Serkan, Kut, Engin, Gulmez, Ahmet, Sakin, Abdullah, Nayir, Erdinc, Acar, Ramazan, Sen, Erdem, Inal, Ali, Turhal, Serdar, Kaya, Ali, Paydas, Semra, Tastekin, Didem, Hacibekiroglu, Ilhan, Cincin, Irfan, Bilici, Ahmet, Mandel, Nil, Dede, Didem, Akinci, Muhammed, Oksuzoglu, Berna, Uncu, Dogan, Yalcin, Bulent, and Artac, Mehmet

Subjects
Metastasis -- Drug therapy -- Patient outcomes, Fluorouracil -- Dosage and administration -- Patient outcomes, Colorectal cancer -- Drug therapy -- Patient outcomes, Drug therapy, Combination -- Patient outcomes, Health
Abstract

Byline: Cihan. Erol, Mehmet. Nahit Sendur, Irem. Bilgetekin, Duygu. Garbioglu, Jamshid. Hamdard, Sinem. Akbas, Mutlu. Hizal, Cagatay. Arslan, Alper. Sevinc, Ahmet. Kucukarda, Dilek. Erdem, Seda. Kahraman, Emre. Cakir, Aykut. Demirkiran, [...]

Published
2022

16. An unusual infection with long-term bevacizumab treatment for advanced nonsmall-cell lung cancer: Actinomycosis

Author

Erol, Cihan, Sendur, Mehmet Nahit, and Yalçin, BüLent

Subjects
Lung cancer, Non-small cell -- Case studies -- Complications and side effects -- Drug therapy, Actinomycosis -- Case studies -- Development and progression -- Care and treatment, Health
Abstract

Byline: Cihan. Erol, Mehmet. Nahit Sendur, Bülent. Yalçin Bevacizumab is an angiogenesis inhibitor with Food and Drug Administration approval for multiple tumor types (including colon, nonsquamous nonsmall-cell lung cancer, kidney [...]

Published
2022

17. The relationship between adjuvant chemotherapy and thiol-disulfide compounds

Author

Akyol, Pinar, Dede, Didem, Bilgin, Burak, Ulas, Arife, Sendur, Mehmet Nahit, Akinci, Muhammed, Baser, Salih, Erol, Cihan, Hizal, Mutlu, and Yalçin, BüLent

Subjects
Cancer -- Adjuvant treatment -- Physiological aspects -- Drug therapy, Homeostasis -- Health aspects, Thiols -- Health aspects -- Physiological aspects, Sulfides -- Physiological aspects -- Health aspects, Health
Abstract

Byline: Pinar. Akyol, Didem. Dede, Burak. Bilgin, Arife. Ulas, Mehmet. Nahit Sendur, Muhammed. Akinci, Salih. Baser, Cihan. Erol, Mutlu. Hizal, Bülent. Yalçin Aim: Thiols are the organic compounds of the [...]

Published
2022

18. Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data

Author

Sütcüoğlu, Osman, primary, Doğan, Akif, additional, Yılmaz, Funda, additional, Şahin, Ahmet Bilgehan, additional, Şahin, Taha Koray, additional, Esin, Selin Aktürk, additional, Erol, Cihan, additional, Üner, Aytuğ, additional, Özet, Ahmet, additional, Turan, Nedim, additional, Eraslan, Emrah, additional, Deligönül, Adem, additional, Odabaş, Hatice, additional, Günel, Nazan, additional, Uçar, Gökhan, additional, Dede, Didem Şener, additional, Dizdar, Ömer, additional, Çubukçu, Erdem, additional, Öksüzoğlu, Ömür Berna, additional, Emre Yıldırım, Mahmut, additional, Yazıcı, Ozan, additional, and Özdemir, Nuriye, additional

Published
2023
Full Text
View/download PDF

19. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Author

Kahraman, Seda, primary, Erul, Enes, additional, Seyyar, Mustafa, additional, Gumusay, Ozge, additional, Bayram, Ertugrul, additional, Demirel, Burcin Cakan, additional, Acar, Omer, additional, Aksoy, Sercan, additional, Baytemur, Naziyet Kose, additional, Sahin, Elif, additional, Cabuk, Devrim, additional, Basaran, Gul, additional, Paydas, Semra, additional, Yaren, Arzu, additional, Guven, Deniz Can, additional, Erdogan, Atike Pinar, additional, Demirci, Umut, additional, Yasar, Alper, additional, Bayoglu, İbrahim Vedat, additional, Hizal, Mutlu, additional, Gulbagci, Burcu, additional, Paksoy, Nail, additional, Davarci, Sena Ece, additional, Yilmaz, Funda, additional, Dogan, Ozlem, additional, Orhan, Sibel Oyucu, additional, Kayikcioglu, Erkan, additional, Aytac, Ali, additional, Keskinkilic, Merve, additional, Mocan, Eda Eylemer, additional, Unal, Olcun Umit, additional, Aydin, Esra, additional, Yucel, Hakan, additional, Isik, Deniz, additional, Eren, Onder, additional, Uluc, Basak Oyan, additional, Ozcelik, Melike, additional, Hacibekiroglu, Ilhan, additional, Aydiner, Adnan, additional, Demir, Hacer, additional, Oksuzoglu, Berna, additional, Cilbir, Ebru, additional, Cubukcu, Erdem, additional, Cetin, Bulent, additional, Oktay, Esin, additional, Erol, Cihan, additional, Okutur, Sadi Kerem, additional, Yildirim, Nilgun, additional, Alkan, Ali, additional, Selcukbiricik, Fatih, additional, Aksoy, Asude, additional, Karakas, Yusuf, additional, Ozkanli, Gulhan, additional, Duman, Berna Bozkurt, additional, Aydin, Dincer, additional, Dulgar, Ozgecan, additional, Er, Muhammed Muhiddin, additional, Teker, Fatih, additional, Yavuzsen, Tugba, additional, Aykan, Musa Baris, additional, Inal, Ali, additional, Iriagac, Yakup, additional, Kalkan, Nurhan Onal, additional, Keser, Murat, additional, Sakalar, Teoman, additional, Menekse, Serkan, additional, Kut, Engin, additional, Bilgin, Burak, additional, Karaoglanoglu, Muge, additional, Sunar, Veli, additional, Ozdemir, Ozlem, additional, Turhal, Nazim Serdar, additional, Karadurmus, Nuri, additional, Yalcin, Bulent, additional, and Nahit Sendur, Mehmet Ali, additional

Published
2023
Full Text
View/download PDF

20. Major and minor salivary gland cancers: A multicenter retrospective study

Author

Hacioglu, Muhammet Bekir, primary, Erdogan, Bulent, additional, Bardakcı, Murat, additional, Algın, Efnan, additional, Gulbagcı, Burcu, additional, Hacibekiroglu, Ilhan, additional, Hamdard, Jamshid, additional, Olmez, Omer Fatih, additional, Akkus, Hadi, additional, Oksuzoglu, Berna, additional, Goksu, Sema Sezgin, additional, Dae, Shute Ailia, additional, Sumbul, Ahmet Taner, additional, Ugraklı, Muzaffer, additional, Karaagac, Mustafa, additional, Sahin, Elif, additional, Cabuk, Devrim, additional, Ozer, Ozden, additional, Yavuzsen, Tugba, additional, Arıkan, Rukiye, additional, Köstek, Osman, additional, Atcı, Muhammed Mustafa, additional, Sakin, Abdullah, additional, Deligonul, Adem, additional, Bayır, Duygu, additional, Dincer, Murat, additional, Unsal, Oktay, additional, Yazıcı, Ozan, additional, Zeynelgil, Esra, additional, Gulmez, Ahmet, additional, Harputluoglu, Hakan, additional, Erol, Cihan, additional, Sendur, Mehmet Ali Nahit, additional, Aytekin, Aydin, additional, Akagunduz, Baran, additional, Oner, Irem, additional, Er, Ozlem, additional, Oztosun, Bugra, additional, Gumus, Mahmut, additional, Biricik, Fatih Selcuk, additional, Aykan, Musa Baris, additional, Karadurmus, Nuri, additional, Degerli, Ezgi, additional, Demirci, Nebi Serkan, additional, Turkmen, Esma, additional, Şakalar, Teoman, additional, Secmeler, Saban, additional, Tanrıverdi, Ozgur, additional, Alkan, Ali, additional, Kemal, Yasemin, additional, Cil, Ibrahim, additional, Unal, Caglar, additional, Iriagaç, Yakup, additional, Alan, Ozkan, additional, Balli, Sevinc, additional, Urun, Yuksel, additional, Ozcan, Erkan, additional, Turhal, Nazım Serdar, additional, and Cicin, Irfan, additional

Published
2023
Full Text
View/download PDF

21. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

Author

Erol, Cihan, primary, Hafızoğlu, Emre, additional, Aykan, Musa Barış, additional, Güven, Deniz Can, additional, Dursun, Bengü, additional, Hızal, Mutlu, additional, Kahraman, Seda, additional, Şener Dede, Didem, additional, Akıncı, Muhammed Bülent, additional, Karadurmuş, Nuri, additional, Ürün, Yüksel, additional, Algın, Efnan, additional, Yalçın, Şuayib, additional, Yalçın, Bülent, additional, and Şendur, Mehmet Ali Nahit, additional

Published
2023
Full Text
View/download PDF

22. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Author

EROL, Cihan, primary, BARDAKÇI, Murat, additional, HIZAL, Mutlu, additional, KAHRAMAN, Seda, additional, YEKEDÜZ, Emre, additional, GÜVEN, Deniz Can, additional, AYKAN, Musa Barış, additional, AK, Recep, additional, ATEŞ, Öztürk, additional, ŞENER DEDE, Didem, additional, AKINCI, Muhammed Bülent, additional, KARADURMUŞ, Nuri, additional, BAL, Öznur, additional, ÜRÜN, Yüksel, additional, YALÇIN, Şuayib, additional, YALÇIN, Bülent, additional, and ŞENDUR, Mehmet Ali Nahit, additional

Published
2023
Full Text
View/download PDF

23. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

Author

Gürbüz, Mustafa, primary, Kiliçkap, Saadettin, additional, Bilici, Ahmet, additional, Karadurmuş, Nuri, additional, Sezer, Ahmet, additional, Şendur, Mehmet Ali Nahit, additional, Paydaş, Semra, additional, Artaç, Mehmet, additional, Fulden Yumuk, Perran, additional, Gürsoy, Pinar, additional, Uysal, Mükremin, additional, Şenol Coşkun, Hasan, additional, Tatli, Ali Murat, additional, Selçukbiricik, Fatih, additional, Dişel, Umut, additional, Köksoy, Elif Berna, additional, Güven, Deniz Can, additional, Uğrakli, Muzaffer, additional, Akkuş, Erman, additional, Yücel, Şebnem, additional, Erol, Cihan, additional, Karakaya, Serdar, additional, Şakalar, Teoman, additional, Khanmammadov, Nijat, additional, Paksoy, Nail, additional, and Demirkazik, Ahmet, additional

Published
2022
Full Text
View/download PDF

24. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.

Author

Erol, Cihan, Yekedüz, Emre, Tural, Deniz, Karakaya, Serdar, Şentürk Öztaş, Nihan, Uçar, Gökhan, Kılıçkap, Saadettin, Ertürk, İsmail, Sever, Özlem Nuray, Arslan, Çağatay, Küçükarda, Ahmet, Can, Orçun, Balvan, Özlem, Yazgan, Satı Coşkun, Özgüroğlu, Mustafa, Öksüzoğlu, Berna, Şendur, Mehmet Ali Nahit, and Ürün, Yüksel

Subjects
*RENAL cell carcinoma, *PROGNOSIS, *RENAL cancer, *CONSORTIA, *DISEASE risk factors, *SURVIVAL rate
Abstract

Introduction: We aimed to evaluate clinical features, prognostic factors, and treatment preferences in patients with non-clear cell renal cell carcinoma (nccRCC). Methods: Patients with metastatic nccRCC were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. Clinical features, prognostic factors, and overall survival (OS) outcomes were investigated. Results: A total of 118 patients diagnosed with nccRCC were included in this study. The median age at diagnosis was 62 years (interquartile range: 56–69). Papillary (57.6%) and chromophobe tumors (12.7%) are common histologic subtypes. Sarcomatoid differentiation was present in 19.5% of all patients. When the patients were categorized according to the International Metastatic RCC Database Consortium (IMDC) risk scores, 66.9% of the patients were found to be in the intermediate or poor risk group. Approximately half of the patients (55.9%) received interferon in the first line. At the median follow-up of 53.2 months (95% confidence interval [CI]: 34.7–71.8), the median OS was 19.3 months (95% CI: 14.1–24.5). In multivariate analysis, lung metastasis (hazard ratio [HR]:2.22, 95% CI: 1.23–3.99) and IMDC risk score (HR: 2.35, 95% CI: 1.01–5.44 for intermediate risk; HR: 8.86, 95% CI: 3.47–22.61 for poor risk) were found to be independent prognostic factors. Conclusion: In this study, survival outcomes are consistent with previous studies. The IMDC risk score and lung metastasis are the independent prognostic factors for OS. This is an area that needs research to better treat this group of patients and create new treatment options. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Author

Yekedüz, Emre, primary, Özbay, Mehmet Fatih, additional, Çağlayan, Dilek, additional, Yıldırım, Atila, additional, Erol, Cihan, additional, Yıldırım, Hasan Çağrı, additional, Tunç, Sezai, additional, Özyurt, Neslihan, additional, Özdemir, Feyyaz, additional, Şendur, Mehmet Ali Nahit, additional, Işıkdoğan, Abdurrahman, additional, Kılıçkap, Saadettin, additional, Ürün, Yüksel, additional, Yalçın, Şuayib, additional, Artaç, Mehmet, additional, Coşkun, Hasan Şenol, additional, and Utkan, Güngör, additional

Published
2022
Full Text
View/download PDF

26. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

Author

Yumuk, Perran Fulden; Selçukbiricik, Fatih (ORCID 0000-0002-1273-1674 & YÖK ID 202015), Gürbüz, Mustafa; Kiliçkap, Saadettin; Bilici, Ahmet; Karadurmuş, Nuri; Sezer, Ahmet; Şendur, Mehmet Ali Nahit; Paydaş, Semra; Artaç, Mehmet; Gürsoy, Pinar; Uysal, Mükremin; Şenol Coşkun, Hasan; Tatli, Ali Murat; Dişel, Umut; Köksoy, Elif Berna; Güven, Deniz Can; U?rakli, Muzaffer; Akkuş, Erman; Yücel, Şebnem; Erol, Cihan; Karakaya, Serdar; Şakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazik, Ahmet, School of Medicine, Yumuk, Perran Fulden; Selçukbiricik, Fatih (ORCID 0000-0002-1273-1674 & YÖK ID 202015), Gürbüz, Mustafa; Kiliçkap, Saadettin; Bilici, Ahmet; Karadurmuş, Nuri; Sezer, Ahmet; Şendur, Mehmet Ali Nahit; Paydaş, Semra; Artaç, Mehmet; Gürsoy, Pinar; Uysal, Mükremin; Şenol Coşkun, Hasan; Tatli, Ali Murat; Dişel, Umut; Köksoy, Elif Berna; Güven, Deniz Can; U?rakli, Muzaffer; Akkuş, Erman; Yücel, Şebnem; Erol, Cihan; Karakaya, Serdar; Şakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazik, Ahmet, and School of Medicine

Abstract

Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited real-life data. Aim of this study is to investigate real-life efficacy and safety of crizotinib in patients with advanced NSCLC harboring MET alterations. This was a retrospective, multicenter (17 centers) study of Turkish Oncology Group. Patients' demographic, histological data, treatment, response rates, survival outcomes, and toxicity data were collected. Outcomes were presented for the study population and compared between MET alteration types. Total of 62 patients were included with a median age of 58.5 (range, 26-78). Major histological type was adenocarcinoma, and 3 patients (4.8%) had sarcomatoid component. The most common MET analyzing method was next generation sequencing (90.3%). MET amplification and mutation frequencies were 53.2% (n?=?33) and 46.8% (n?=?29), respectively. Overall response rate and disease control rate were 56.5% and 74.2% in whole study population, respectively. Median progression free survival (PFS) was 7.2 months (95% confidence interval [CI]: 3.8-10.5), and median overall survival (OS) was 18.7 months (95% CI: 13.7-23.7), regardless of treatment line. Median PFS was 6.1 months (95% CI: 5.6-6.4) for patients with MET amplification, whereas 14.3 months (95% CI: 6.7-21.7) for patients with MET mutation (P?=?.217). Median PFS was significantly longer in patients who have never smoked (P?=?.040), have good performance score (P?

Published
2022

27. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

Author

Başoğlu, Tuğba, primary, Sakin, Abdullah, additional, Erol, Cihan, additional, Özden, Ercan, additional, Çabuk, Devrim, additional, Çılbır, Ebru, additional, Tataroğlu Özyükseler, Deniz, additional, Ayhan, Murat, additional, Şendur, Mehmet Ali, additional, Dogan, Mutlu, additional, Öksüzoğlu, Berna, additional, Eryılmaz, Melek Karakurt, additional, Er, Özlem, additional, Taşçı, Elif Şenocak, additional, Özyurt, Neslihan, additional, Dülgar, Özgecan, additional, Özen, Miraç, additional, Hacıbekiroğlu, İlhan, additional, Öner, İrem, additional, Bekmez, Esma Türkmen, additional, Çağrı Yıldırım, Hasan, additional, Yalçın, Şuayib, additional, Paydaş, Semra, additional, Yekedüz, Emre, additional, Aksoy, Asude, additional, Özçelik, Melike, additional, Oyman, Abdilkerim, additional, Almuradova, Elvina, additional, Karabulut, Bülent, additional, Demir, Nazan, additional, Dinçer, Murat, additional, Özdemir, Nuriye, additional, Erdem, Dilek, additional, Ak, Naziye, additional, İnal, Ali, additional, Salim, Derya Kıvrak, additional, Deniz, Gülhan İpek, additional, Şakalar, Teoman, additional, Gülmez, Ahmet, additional, Kaçan, Turgut, additional, Özdemir, Özlem, additional, Alan, Özkan, additional, Ünal, Çağlar, additional, Karakaş, Yusuf, additional, Turhal, Serdar, additional, and Yumuk, Perran Fulden, additional

Published
2022
Full Text
View/download PDF

28. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma

Author

Aktürk Esen, Selin, primary, Ergun, Yakup, additional, Erol, Cihan, additional, Arikan, Rukiye, additional, Er, Muhammed Muhiddin, additional, Atci, Muhammed Mustafa, additional, Topçu, Atakan, additional, Uçar, Gökhan, additional, Akagündüz, Baran, additional, Aykan, Musa Bariş, additional, Özen, Miraç, additional, Baytemur, Naziyet Köse, additional, Özçelik, Melike, additional, Şahin, Elif, additional, Güven, Denizcan, additional, Menekşe, Serkan, additional, Ak, Naziye, additional, Teker, Fatih, additional, Kut, Engin, additional, Şakalar, Teoman, additional, Alan, Özkan, additional, Kaçan, Turgut, additional, Turhal, Nazim Serdar, additional, Kiliçkap, Saadettin, additional, Türker, Sema, additional, Şendur, Mehmet Ali Nahit, additional, Köstek, Osman, additional, Karaağaç, Mustafa, additional, Sakin, Abdullah, additional, Türk, Haci Mehmet, additional, Çağlayan, Dilek, additional, Cihan, Şener, additional, Açikgöz, Yusuf, additional, and Uncu, Doğan, additional

Published
2022
Full Text
View/download PDF

29. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

Author

Ürün, Yüksel, primary, Yekedüz, Emre, additional, Tural, Deniz, additional, Ertürk, İsmail, additional, Karakaya, Serdar, additional, Erol, Cihan, additional, Ercelep, Özlem, additional, Arslan, Çağatay, additional, Sever, Özlem Nuray, additional, Kılıçkap, Saadettin, additional, Öztaş, Nihan Şentürk, additional, Küçükarda, Ahmet, additional, Can, Orçun, additional, Öksüzoğlu, Berna, additional, Şendur, Mehmet Ali, additional, and Karadurmuş, Nuri, additional

Published
2022
Full Text
View/download PDF

30. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Author

Özen, Miraç, Teker, Fatih, Ak, Naziye, Menekşe, Serkan, Güven, Denizcan, Şahin, Elif, Özçelik, Melike, Baytemur, Naziyet Köse, Aykan, Musa Bariş, Akagündüz, Baran, Uçar, Gökhan, Topçu, Atakan, Atci, Muhammed Mustafa, Er, Muhammed Muhiddin, Arikan, Rukiye, Erol, Cihan, Ergun, Yakup, Esen, Selin Aktürk, TÜRK, HACI MEHMET, Uncu, Doğan, Açikgöz, Yusuf, Cihan, Şener, Çağlayan, Dilek, Sakin, Abdullah, Karaağaç, Mustafa, Köstek, Osman, Şendur, Mehmet Ali Nahit, Türker, Sema, Kiliçkap, Saadettin, Turhal, Nazim Serdar, Kaçan, Turgut, Alan, Özkan, Şakalar, Teoman, Kut, Engin, and TÜRK, HACI MEHMET

Subjects
Esophageal Neoplasms, Receptor, ErbB-2, Leucovorin, Middle Aged, Trastuzumab, Oxaliplatin, Esen S. A. , Ergun Y., Erol C., Arikan R., Er M. M. , Atci M. M. , Topçu A., Uçar G., Akagündüz B., Aykan M. B. , et al., -First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer-, Bosnian Journal of Basic Medical Sciences, cilt.22, sa.5, ss.818-825, 2022, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Esophagogastric Junction, Fluorouracil, Cisplatin, Retrospective Studies
Abstract

© The Author(s) (2022).Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which plati-num-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received f luorouracil, oxaliplatin, and leucovo-rin (mFOLFOX)+trastuzumab or cisplatin and f luorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLF-OX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (p = 0.495). About 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (p = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, p = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, p = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, mFOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens.

Published
2022

31. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Author

Akturk Esen, Selin, Ergun, Yakup, Erol, Cihan, Arikan, Rukiye, Er, Muhammed Muhiddin, İstinye Üniversitesi, Hastane, Kilickap, Saadettin, and AAP-3732-2021

Subjects
Gastric Cancer, FOLFOX, Gastroesophageal Junction Cancer, CF, Trastuzumab
Abstract

Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which plati-num-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received f luorouracil, oxaliplatin, and leucovo-rin (mFOLFOX)+trastuzumab or cisplatin and f luorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLF-OX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (p = 0.495). About 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (p = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, p = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, p = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, mFOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens.

Published
2022

32. Pazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study

Author

Bilici, Ahmet, Koca, Sinan, Karaağaç, Mustafa, Eraslan, Emrah, Ocak, Birol, Göktaş Aydın, Sabin, Göksu, Sema Sezgin, Paydaş, Semra, Derin, Sümeyye, Ergün, Yakup, Yekegündüz, Emre, Erol, Cihan, Tataroğlu Özyükseler, Deniz, Demiray, Atike Gökçen, Karaca, Mustafa, Güç, Zeynep Gülsüm, Menekşe, Serkan, Çınkır, Havva Yeşil, Gümüşay, Özge, and Sakin, Abdullah

Subjects
Soft Tissue Sarcoma (STS), Metastatic, Multi-Institutional Observational Study
Published
2022

33. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study.

Author

Başoğlu, Tuğba, Sakin, Abdullah, Erol, Cihan, Özden, Ercan, Çabuk, Devrim, Çılbır, Ebru, Tataroğlu Özyükseler, Deniz, Ayhan, Murat, Şendur, Mehmet Ali, Dogan, Mutlu, Öksüzoğlu, Berna, Eryılmaz, Melek Karakurt, Er, Özlem, Taşçı, Elif Şenocak, Özyurt, Neslihan, Dülgar, Özgecan, Özen, Miraç, Hacıbekiroğlu, İlhan, Öner, İrem, and Bekmez, Esma Türkmen

Published
2023
Full Text
View/download PDF

34. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.

Author

Kahraman, Seda, Bardakci, Murat, Aykan, Musa B., Yasar, Serkan, Erol, Cihan, Hizal, Mutlu, Bulent Akinci, M., Kos, Fahriye Tugba, Dede, Didem S., Karadurmus, Nuri, Yalcin, Suayib, Sendur, Mehmet Ali N., and Yalcin, Bulent

Subjects
NEUROENDOCRINE tumors, LOG-rank test, PANCREATIC tumors, NEUROENDOCRINE system, CLINICAL pathology, RETROSPECTIVE studies
Abstract

Objective: Neuroendocrine neoplasms(NENs) originate from the diffuse neuroendocrine cell system and constitute a heterogeneous group of tumors exhibiting diverse clinical and biological characteristics. NENs include well‑differentiated neuroendocrine tumors(NETs) and poorly differentiated neuroendocrine carcinomas (NECs). In the present study, we performed a retrospective analysis of patients diagnosed with NET to evaluate clinicopathological characteristics, treatment and outcomes. Material and Methods: Data from 153 patients diagnosed with NET who were treated and followed up at three tertiary care centers from November 2002 to June 2021 were retrospectively evaluated. Clinicopathological and prognostic factors, treatment modalities and survival data were analyzed. Kaplan–Meier analysis was used to assess survival data and comparisons were performed using the logrank test. Results: Median age (IQR) was 53 (18–80) years. 85.6% of the patients had gastro‑entero‑pancreatic (GEP)‑NET. The primary tumor was resected in 95 patients (62.1%) and metastasectomy were performed in 22 patients (14.4%). Seventy‑eight patients received systemic therapy for metastatic disease. Patients were followed up for a median of 22 (IQR = 33.8) months. The estimated one‑year and three‑year survival rate was 89.8% and 74.4%, respectively. Median progression‑free survival (PFS) were 10.1, 8.5, and 4.2 months after first‑, second‑ and third‑line therapy, respectively. Conclusion: The number of systemic treatment options and diagnostic tools for NETs has significantly improved in the last few years. NET classification, which treatment will be more appropriate for which group of patients, the molecular basis of this disease and the development of treatment strategies are open‑ended questions that still need to be investigated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Author

EROL, CİHAN, primary, SAKİN, ABDULLAH, additional, TÜYLÜ, TUĞBA BAŞOĞLU, additional, ÖZDEN, ERCAN, additional, ÇABUK, DEVRİM, additional, DOĞAN, MUTLU, additional, ÖKSÜZOĞLU, ÖMÜR BERNA ÇAKMAK, additional, YILDIRIM, HASAN ÇAĞRI, additional, ÖNER, İREM, additional, ERYILMAZ, MELEK KARAKURT, additional, DÜLGAR, ÖZGECAN, additional, AYDIN, DİNÇER, additional, ÖZYURT, NESLİHAN, additional, ÖZEN, MİRAÇ, additional, and HACIBEKİROĞLU, İLHAN, additional

Published
2022
Full Text
View/download PDF

38. Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study

Author

GÜRBÜZ, Mustafa, primary, DOĞAN, İzzet, additional, AKKUŞ, Erman, additional, KARADAĞ, İbrahim, additional, KARAKAYA, Serdar, additional, EROL, Cihan, additional, ACAR, Ramazan, additional, KARAOĞLAN, Mert, additional, KÖKSOY, Elif Berna, additional, SAVAŞ, Berna, additional, ŞENDUR, Mehmet Ali Nahit, additional, TAŞTEKİN, Didem, additional, KARADURMUŞ, Nuri, additional, ÇAKMAK ÖKSÜZOĞLU, Ömür Berna, additional, and ÇAY ŞENLER, Filiz, additional

Published
2022
Full Text
View/download PDF

40. The Relationship Between Systemic Immune Inflammation Index and Treatment Response in Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors: Results from The Turkish Oncology Group Kidney Cancer Consortium Database

Author

Yücel, Kadriye Bir, primary, Yekedüz, Emre, additional, Karakaya, Serdar, additional, Tural, Deniz, additional, Ertürk, İsmail, additional, Erol, Cihan, additional, Ercelep, Özlem, additional, Öztaş, Nihan Şentürk, additional, Arslan, Çağatay, additional, Uçar, Gökhan, additional, Küçükarda, Ahmet, additional, Sever, Özlem Nuray, additional, Kılıçkap, Saadettin, additional, Can, Orçun, additional, Yazgan, Satı Coşkun, additional, Öksüzoğlu, Berna, additional, Karadurmuş, Nuri, additional, Şendur, Mehmet Ali, additional, and Ürün, Yüksel, additional

Published
2021
Full Text
View/download PDF

41. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real‐world chronic hepatitis C patients cohort

Author

Alkim, Huseyin, Kaymakoglu, Sabahattin, TABAK, Ömer Fehmi, GÜNŞAR, FULYA, AKHAN, SILA, İDİLMAN, RAMAZAN, DEMİR, MEHMET, ALADAĞ, MURAT, Erol, Cihan, Cavus, Bilger, Iliaz, Raim, Koklu, Hayrettin, Cakaloglu, Yilmaz, Sahin, Memduh, ERSÖZ, GALİP, Koksal, Iftihar, KARASU, ABDULLAH ZEKİ, Ozgenel, Meric, TURAN, İLKER, GÜNDÜZ, FEYZA, ATASEVEN , HÜSEYİN, Akdogan, Meral, KIYICI, MURAT, Ozkan, Hasan, Ozer, Birol, AKARSU, MESUT, Kuruuzum, Ziya, Yurdaydin, Cihan, Yozgat, Ahmet, Yilmaz, Hasan, Yilmaz, Bulent, Yildirim, Beytullah, Yildirim, Abdullah E., KÖKSAL, AYDIN ŞEREF, Yaras, Serkan, Unal, Hakan, Toka, Bilal, Simsek, Halis, Senates, Ebubekir, Poturoglu, Sule, Ozenirler, Seren, Ozbakir, Omer, Ormeci, Necati, ÖNDER, Fatih Oğuz, Kav, Taylan, Kamilli, Cemil, Inkaya, Ahmet Cagan, Gursoy, Sebnem, Gurel, Selim, Gokcan, Hale, Ensaroglu, Fatih, Cosgun, Suleyman, Celik, Ilhami, Bolat, Aylin, Baysal, Birol, Barut, Huseyin S., Balik, Ismail, Aygen, Bilgehan, Ates, Fehmi, Araz, Filiz, Akarca, Ulus S., Idilman, R, Demir, M, Aladag, M, Erol, C, Cavus, B, Iliaz, R, Koklu, H, Cakaloglu, Y, Sahin, M, Ersoz, G, Koksal, I, Karasu, Z, Ozgenel, M, Turan, I, Gunduz, F, Ataseven, H, Akdogan, M, Kiyici, M, Koksal, AS, Akhan, S, Gunsar, F, Tabak, F, Kaymakoglu, S, Akarca, US, Akarsu, M, Alkim, H, Araz, F, Ates, F, Aygen, B, Balik, I, Barut, HS, Baysal, B, Bolat, A, Celik, I, Cosgun, S, Ensaroglu, F, Gokcan, H, Gurel, S, Gursoy, S, Inkaya, AC, Kamilli, C, Kav, T, Kuruuzum, Z, Onder, FO, Ormeci, N, Ozbakir, O, Ozenirler, S, Ozer, B, Ozkan, H, Poturoglu, S, Senates, E, Simsek, H, Toka, B, Unal, H, Yaras, S, Yildirim, AE, Yildirim, B, Yilmaz, B, Yilmaz, H, Yozgat, A, Yurdaydin, C, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Köksal, Aydın Şeref, and Toka, Bilal

Subjects
Male, Cirrhosis, Sustained Virologic Response, Sofosbuvir, viruses, medicine.medical_treatment, Hepacivirus, Liver transplantation, Gastroenterology, Cohort Studies, chemistry.chemical_compound, Liver disease, 0302 clinical medicine, 030212 general & internal medicine, Aged, 80 and over, Liver Neoplasms, Middle Aged, Infectious Diseases, Hepatocellular carcinoma, RNA, Viral, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Uridine Monophosphate, medicine.drug, Adult, Ledipasvir, medicine.medical_specialty, Carcinoma, Hepatocellular, Genotype, Antiviral Agents, 03 medical and health sciences, Virology, Internal medicine, Ribavirin, medicine, Humans, Aged, Fluorenes, Hepatology, business.industry, Hepatitis C, Chronic, medicine.disease, digestive system diseases, Liver Transplantation, chemistry, Benzimidazoles, Liver function, Neoplasm Recurrence, Local, business
Abstract

The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22 months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P < 0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6 months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P = 0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.

Published
2019
Full Text
View/download PDF

42. Real Life Experience of Patients With Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma Treated With Neoadjuvant Chemotherapy: a Turkish Oncology Group Study

Author

Basoglu, Tugba, primary, erol, cihan, additional, sakin, abdullah, additional, özden, ercan, additional, çabuk, devrim, additional, çılbır, ebru, additional, özyükseler, deniz tataroğlu, additional, ayhan, murat, additional, şendur, mehmet ali, additional, doğan, mutlu, additional, öksüzoğlu, berna, additional, eryılmaz, melek karakurt, additional, er, özlem, additional, taşçı, elif şenocak, additional, doğan, nelihan, additional, dülgar, özgecan, additional, özen, miraç, additional, hacıbekiroğlu, ilhan, additional, öner, irem, additional, bekmez, esma türkmen, additional, yıldırım, hasan çağrı, additional, yalçın, şuayib, additional, paydaş, semra, additional, yekedüz, emre, additional, aksoy, asude, additional, özçelik, melike, additional, oyman, abdilkerim, additional, almuradova, elvina, additional, karabulut, bülent, additional, demir, nazan, additional, dinçer, murat, additional, erdem, dilek, additional, ak, naziye, additional, inal, ali, additional, salim, derya kıvrak, additional, deniz, gülhan ipek, additional, gülmez, ahmet, additional, kaçan, turgut, additional, özdemir, özlem, additional, alan, özkan, additional, ünal, çağlar, additional, turhal, serdar, additional, karakaş, yusuf, additional, and yumuk, perran fulden, additional

Published
2021
Full Text
View/download PDF

44. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Author

Hizal, Mutlu, primary, Bilgin, Burak, additional, Paksoy, Nail, additional, Açıkgöz, Özgür, additional, Sezer, Ahmet, additional, Gürbüz, Mustafa, additional, Ak, Naziye, additional, Yücel, Şebnem, additional, Ayhan, Murat, additional, Erol, Cihan, additional, Demirkıran, Aykut, additional, Mandel, Nil Molinas, additional, Shbair, Abdallah, additional, Gökmen, İvo, additional, Başoğlu, Tuğba, additional, Paydaş, Semra, additional, Demiray, Atike Gökçen, additional, İriağaç, Yakup, additional, Şakalar, Teoman, additional, Zeynelgil, Esra, additional, Tatlı, Ali Murat, additional, Bahçeci, Aykut, additional, Güven, Deniz Can, additional, Caner, Burcu, additional, Can, Alper, additional, Gülmez, Ahmet, additional, Karakaş, Yusuf, additional, Yalçın, Bülent, additional, Demirkazık, Ahmet, additional, Bilici, Ahmet, additional, Aydıner, Adnan, additional, Yumuk, Perran Fulden, additional, and Şendur, Mehmet Ali Nahit, additional

Published
2021
Full Text
View/download PDF

45. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.

Author

Esen, Selin Aktürk, Ergun, Yakup, Erol, Cihan, Arikan, Rukiye, Er, Muhammed Muhiddin, Atci, Muhammed Mustafa, Topçu, Atakan, Uçar, Gökhan, Akagündüz, Baran, Aykan, Musa Bariş, Özen, Miraç, Baytemur, Naziyet Köse, Özçelik, Melike, Şahin, Elif, Güven, Denizcan, Menekşe, Serkan, Ak, Naziye, Teker, Fatih, Kut, Engin, and Şakalar, Teoman

Published
2022
Full Text
View/download PDF

46. Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Author

Gürbüz, Mustafa, primary, Akkuş, Erman, additional, Sakin, Abdullah, additional, Urvay, Semiha, additional, Demiray, Atike Gökçen, additional, Şahin, Süleyman, additional, Şakalar, Teoman, additional, Erol, Cihan, additional, Şendur, Mehmet Ali Nahit, additional, Şahin, Ahmet Bilgehan, additional, Çubukçu, Erdem, additional, Güven, Deniz Can, additional, Kılıçkap, Saadettin, additional, Ergün, Yakup, additional, Uncu, Doğan, additional, Turhal, Nazım Serdar, additional, Üskent, Necdet, additional, Çınkır, Havva Yeşil, additional, Demir, Atakan, additional, Acar, Ramazan, additional, Karadurmuş, Nuri, additional, Türker, Sema, additional, Altınbaş, Mustafa, additional, Karaoğlan, Mert, additional, and Şenler, Filiz Çay, additional

Published
2021
Full Text
View/download PDF

47. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer

Author

Gürbüz, Mustafa, primary, Akkuş, Erman, additional, Sakin, Abdullah, additional, Urvay, Semiha, additional, Demiray, Atike Gökçen, additional, Şahin, Süleyman, additional, Şakalar, Teoman, additional, Erol, Cihan, additional, Şendur, Mehmet ali Nahit, additional, Şahin, Ahmet Bilgehan, additional, Çubukçu, Erdem, additional, Güven, Deniz Can, additional, Kılıçkap, Saadettin, additional, Ergün, Yakup, additional, Uncu, Doğan, additional, Turhal, Nazım Serdar, additional, Üskent, Necdet, additional, Yeşil Çınkır, Havva, additional, Demir, Atakan, additional, Acar, Ramazan, additional, Karadurmuş, Nuri, additional, Türker, Sema, additional, Altınbaş, Mustafa, additional, Karaoğlan, Mert, additional, and Çay Şenler, Filiz, additional

Published
2020
Full Text
View/download PDF

50. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer

Author

Gürbüz, Mustafa, Akkuş, Erman, Sakin, Abdullah, Urvay, Semiha, Demiray, Atike Gökçen, Şahin, Süleyman, Şakalar, Teoman, Erol, Cihan, Şendur, Mehmet ali Nahit, Şahin, Ahmet Bilgehan, Çubukçu, Erdem, Güven, Deniz Can, Kılıçkap, Saadettin, Ergün, Yakup, Uncu, Doğan, Turhal, Nazım Serdar, Üskent, Necdet, Yeşil Çınkır, Havva, Demir, Atakan, Acar, Ramazan, Karadurmuş, Nuri, Türker, Sema, Altınbaş, Mustafa, Karaoğlan, Mert, and Çay Şenler, Filiz

Abstract

Purpose: Taxane-containing combinations are recommended for the first-line therapy of advanced gastric cancer. It is not known which chemotherapy regimen is the best with trastuzumab for HER2-positive patients. The aim of this study was to compare taxane-containing intensified chemotherapy versus standard chemotherapy in combination with trastuzumab in the first-line treatment of HER2-positive advanced gastric adenocarcinoma.Methods: This study is a retrospective multicenter study of the Turkish Oncology Group. A total of 130 HER2-positive patients with inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma being given chemotherapy plus trastuzumab as the first-line treatment were included from 16 different oncology centers. Trastuzumab combination with intensified chemotherapy including taxane or standard chemotherapy was compared in terms of progression-free survival (PFS), overall survival (OS), and toxicity.Results: There were 108 patients in the standard and 22 patients in the intensified chemotherapy group. PFS of the standard and intensified group were 5.6 months (95% confidence interval [CI] 4.8–6.4) and 5.3 months (95% CI 2.6–8), respectively (p= 0.70). OS of the standard and intensified group were 11.1 months (95% CI 8.3–13.9) and 15.2 months (95% CI 12.7–17.7), respectively (p= 0.03). Repeated analysis excluding patients given any previous therapy revealed similar results. The intensified group had more fever and febrile neutropenia.Conclusion: Trastuzumab combination with intensified chemotherapy provides better OS in first-line treatment of HER2-positive advanced gastric cancer. Further large-scale studies should be performed in HER2-positive patients.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results